Burning Rock Biotech Ltd
BNR Nasdaq· Services-Medical Laboratories
KIRA · Stoqly’s AI analyst, in plain words
- Burning Rock Biotech Ltd had $75.1M of revenue in fiscal 2025, up 4.7% on the year before. Over five years, revenue changed +3.8% a year on average.
- Its operating margin was −10.2%, up 59.2 pts: of every 100 in sales, about −10 is left after running the business.
- Burning Rock Biotech Ltd lost $7.7M in fiscal 2025.
- Free cash flow was −$4.7M in fiscal 2025, −6.2% of revenue.
- Burning Rock Biotech Ltd has $68.1M more cash than debt.
Market cap
—
P/E
—
Revenue
$75.1M
Net income
−$7.7M
Free cash flow
−$4.7M
Operating margin
−10.2%
Burning Rock Biotech Ltd in 30 seconds · fiscal 2025
Are sales growing?
+4.7%
Only a little. Sales grew 4.7% last year.
Does it make a profit?
−10.3%
No. It lost money last year.
Does profit turn into cash?
−6.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
What Burning Rock Biotech Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 28, 2026
- Legal name
- Burning Rock Biotech Ltd
- CIK
- 0001792267
Burning Rock Biotech Ltd · BNR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $78.7M | $83.7M | $75.9M | $71.7M | $75.1M |
| Revenue growth | 26.4% | 6.2% | −9.3% | −5.5% | 4.7% |
| Net interest income | −$0.2M | $0.0M | $0.0M | $0.0M | −$0.0M |
| Gross margin | 71.7% | 67.5% | 67.6% | 70.3% | 74.7% |
| Operating margin | −156.9% | −174.1% | −124.5% | −69.3% | −10.2% |
| Net income | −$124M | −$144M | −$92.3M | −$48.2M | −$7.7M |
| Net margin | −156.9% | −172.4% | −121.6% | −67.2% | −10.3% |
| Diluted EPS | $0.00 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$74.1M | −$67.8M | −$36.1M | −$12.8M | −$4.0M |
| Capital expenditure | $31.7M | $9.2M | $1.1M | $0.8M | $0.7M |
| Free cash flow | −$106M | −$77.1M | −$37.3M | −$13.6M | −$4.7M |
| FCF margin | −134.3% | −92.1% | −49.1% | −18.9% | −6.2% |
| Share buybacks | $0.0M | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $235M | $131M | $86.6M | $71.2M | $68.3M |
| Debt incl. finance leases | $0.4M | $0.0M | — | $0.0M | $0.2M |
| Shareholders' equity | $290M | $168M | $108M | $79.6M | $76.5M |
| Current ratio | 4.9x | 3.1x | 3.4x | 2.9x | 3.0x |
| Interest coverage | −518.8x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | −175.9% | −313.8% | — | −469.8% | −72.1% |
| Return on equity | −37.4% | −62.9% | −66.9% | −51.3% | −9.9% |
| Return on tangible equity | −42.6% | −86.1% | −85.4% | −60.6% | −10.1% |
| Piotroski F-score | 4 | 3 | 4 | 4 | 5 |
| Altman Z'' | 3.1 | −4.5 | −9.5 | −12.4 | −11.4 |
Insiders bought, 12 months
$11.6M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Burning Rock Biotech Ltd · BNR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001792267). Data updated October 24, 2026. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.